Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit

дифференцированный рак щитовидной железы, ленватиниб, системная терапия, токсичность, радиойодрефрактерность

1. Davies L., Welch H.G. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140(4):317–22. DOI: 10.1001/jamaoto.2014.1

2. Cabanillas M.E., Habra M.A. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev 2016;42:47–55. DOI: 10.1016/j.ctrv.2015.11.003

3. Bomeli S.R., LeBeau S.O., Ferris R.L. Evaluation of a thyroid nodule. Otolaryngol Clin North Am 2010;43(2):229–38. DOI: 10.1016/j.otc.2010.01.002

4. Filetti S., Durante C., Hartl D. et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(12):1856–83. DOI: 10.1093/annonc/mdz400

5. Busaidy N.L., Cabanillas M.E. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res 2012;2012:618985. DOI: 10.1155/2012/618985

6. Fleeman N., Houten R., Chaplin M. et al. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer 2019;19(1):1209. DOI: 10.1186/s12885-019-6369-7

7. Worden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol 2014;6(6):267– 79. DOI: 10.1177/1758834014548188

8. Aashiq M., Silverman D.A., Na’ara S. et al. Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies. Cancers (Basel) 2019;11(9):1382. DOI: 10.3390/cancers11091382

9. Araque K.A., Gubbi S., Klubo-Gwiezdzinska J. Updates on the management of thyroid cancer. Horm Metab Res 2020;52(8):562– 77. DOI: 10.1055/a-1089-7870

10. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Thyroid Carcinoma. Version 2.2021. Доступно по: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf

11. Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319–28. DOI: 10.1016/S0140-6736(14)60421-9

12. Lenvima (lenvatinib) [prescribing information]. Nutley, NJ: Eisai Inc., 2021.

13. Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI: 10.1056/NEJMoa1406470

14. Gianoukakis A.G., Dutcus C.E., Batty N. et al. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer 2018;25(6):699–704. DOI: 10.1530/ERC-18-0049

15. Matrone A., Campopiano M.C., Nervo A. et al. Differentiated thyroid cancer, from active surveillance to advanced therapy: toward a personalized medicine. Front Endocrinol (Lausanne) 2020;10:884. DOI: 10.3389/fendo.2019.00884

16. Tumino D., Frasca F., Newbold K. Updates on the management of advanced, metastatic, and radioiodine refractory differentiated thyroid cancer. Front Endocrinol (Lausanne) 2017;8:312. DOI: 10.3389/fendo.2017.00312

17. Wassermann J., Bernier M.O., Spano J.P. et al. Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas. Oncologist 2016;21(1):50–8. DOI: 10.1634/theoncologist.2015-0107

18. Tuttle R.M. Initial treatment of progressive differentiated thyroid cancer. Clin Adv Hematol Oncol 2016;14(9):3–6.

19. Fukuda N., Takahashi S. Clinical indications for treatment with multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer. Cancers (Basel) 2021;13(9):2279. DOI: 10.3390/cancers13092279

20. Haugen B.R., Alexander E.K., Bible K.C. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26(1):1–133. DOI: 10.1089/thy.2015.0020

21. Fugazzola L., Elisei R., Fuhrer D. et al. 2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J 2019;8(5):227–45. DOI: 10.1159/000502229

22. Ito Y., Onoda N., Okamoto T. The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer. Endocr J 2020;67(7):669–717. DOI: 10.1507/endocrj.EJ20-0025

23. Templeton A.J., McNamara M.G., Šeruga B. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;10696):dju124. DOI: 10.1093/jnci/dju124

24. Song T., Wan Q., Yu W. et al. Pretreatment nutritional risk scores and performance status are prognostic factors in esophageal cancer patients treated with definitive chemoradiotherapy. Oncotarget 2017;8(58):98974–84. DOI: 10.18632/oncotarget.21940

25. Suzuki C., Kiyota N., Imamura Y. et al. Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer. Head Neck 2019;41(9):3023–32. DOI: 10.1002/hed.25784

26. Taylor M.H., Takahashi S., Capdevila J. et al. Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid 2021;31(8):1226–34. DOI: 10.1089/thy.2020.0779

27. Tahara M., Kiyota N., Hoff A.O. et al. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 2021;147:51–7. DOI: 10.1016/j.ejca.2020.12.032

28. Brose M.S., Panaseykin Y., Konda B. et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab 2021;107(3):776–87. DOI: 10.1210/clinem/dgab1731

29. Tahara M., Brose M.S., Wirth L.J. et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 2019;106:61–8. DOI: 10.1016/j.ejca.2018.10.002

30. Hayato S., Shumaker R., Ferry J. et al. Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer. Cancer Chemother Pharmacol 2018;82(6):971–8. DOI: 10.1007/s00280-018-3687-4

31. Cabanillas M.E., Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol 2019;46(1):57–64. DOI: 10.1053/j.seminoncol.2018.11.004

32. Reed N., Glen H., Gerrard G. et al. Expert consensus on the management of adverse events during treatment with lenvatinib for thyroid cancer. Clin Oncol (R Coll Radiol) 2020;32(5):e145–53. DOI: 10.1016/j.clon.2019.11.010

33. Resteghini C., Cavalieri S., Galbiati D. et al. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best Pract Res Clin Endocrinol Metab 2017;31(3):349–61. DOI: 10.1016/j.beem.2017.04.012

34. Costa R., Carneiro B.A., Chandra S. et al. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther 2016;10:873–84. DOI: 10.2147/DDDT.S93459

35. Valerio L., Giani C., Agate L. et al. Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer. Eur Thyroid J 2021;10(5):399–407. DOI: 10.1159/000514182

36. Lamartina L., Ippolito S., Danis M. et al. Antiangiogenic tyrosine kinase inhibitors: occurrence and risk factors of hemoptysis in refractory thyroid cancer. J Clin Endocrinol Metab 2016;101(7):2733–41. DOI: 10.1210/jc.2015-4391

37. Iwasaki H., Toda S., Ito H. et al. A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy. Case Rep Endocrinol 2020;2020:6438352. DOI: 10.1155/2020/6438352

38. Tsuboi M., Takizawa H., Aoyama M. et al. Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: a case report. Int J Surg Case Rep 2017;41:89–92. DOI: 10.1016/j.ijscr.2017.10.010

39. Das A., Mahapatra S., Bandyopadhyay D. et al. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: a network meta-analysis. Crit Rev Oncol Hematol 2021;157:103186. DOI: 10.1016/j.critrevonc.2020.103186

40. Brose M.S., Worden F.P., Newbold K.L. et al. Effect of age on the efficacy and safety of lenvatinib in radioiodine-fefractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol 2017;35(23):2692–9. DOI: 10.1200/JCO.2016.71.6472

41. Kiyota N., Robinson B., Shah M. et al. Defining radioiodine-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib y radioiodine-refractory criteria in the SELECT trial. Thyroid 2017;27(9):1135–41. DOI: 10.1089/thy.2016.0549

42. Makihara R.A., Narita S.N., Yamamoto N. et al. Relationships between lenvatinib plasma concentration and toxicity in Japanese cancer patients [abstract]. Ann Oncol 2018;29(Suppl. 9):ix23.

43. Verheijen R.B., Yu H., Schellens J.H.M. et al. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 2017;102(5):765–76. DOI: 10.1002/cpt.787

44. Gomes-Lima C.J., Wu D., Rao S.N. et al. Brain metastases from differentiated thyroid carcinoma: prevalence, current therapies, and outcomes. J Endocr Soc 2019;3(2):359–71. DOI: 10.1210/js.2018-00241

45. Liu M., Shen Y., Ruan M. et al. Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma. Thyroid 2014;24(7):1179– 83. DOI: 10.1089/thy.2013.0703

46. Nervo A., Ragni A., Retta F. et al. Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues. J Endocrinol Invest 2021;44(3):403–19. DOI: 10.1007/s40618-020-01374-7

47. Motzer R., Alekseev B., Rha S.Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384(14):1289–300. DOI: 10.1056/NEJMoa2035716

48. Makker V., Colombo N., Casado Herraez A. et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022;386(5):437–48. DOI: 10.1056/NEJMoa2108330